4.5 Article

The McKenzie Method Compared With Manipulation When Used Adjunctive to Information and Advice in Low Back Pain Patients Presenting With Centralization or Peripheralization A Randomized Controlled Trial

Journal

SPINE
Volume 36, Issue 24, Pages 1999-2010

Publisher

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/BRS.0b013e318201ee8e

Keywords

low back pain; chronic disease; McKenzie treatment; physical therapy; chiropractic manipulation; exercise

Ask authors/readers for more resources

Study Design. Randomized controlled trial. Objective. To compare the effects of the McKenzie method performed by certified therapists with spinal manipulation performed by chiropractors when used adjunctive to information and advice. Summary of Background Data. Recent guidelines recommend a structured exercise program tailored to the individual patient as well as manual therapy for the treatment of persistent low back pain. There is presently insufficient evidence to recommend the use of specific decision methods tailoring specific therapies to clinical subgroups of patients in primary care. Methods. A total of 350 patients suffering from low back pain with a duration of more than 6 weeks who presented with centralization or peripheralization of symptoms with or without signs of nerve root involvement, were enrolled in the trial. Main outcome was number of patients with treatment success defined as a reduction of at least 5 points or an absolute score below 5 points on the Roland Morris Questionnaire. Secondary outcomes were reduction in disability and pain, global perceived effect, general health, mental health, lost work time, and medical care utilization. Results. Both treatment groups showed clinically meaningful improvements in this study. At 2 months follow-up, the McKenzie treatment was superior to manipulation with respect to the number of patients who reported success after treatment (71% and 59%, respectively) (odds ratio 0.58, 95% confidence interval [CI] 0.36 to 0.91, P = 0.018). The number needed to treat with the McKenzie method was 7 (95% CI 4 to 47). The McKenzie group showed improvement in level of disability compared to the manipulation group reaching a statistical significance at 2 and 12 months follow-up (mean difference 1.5, 95% CI 0.2 to 2.8, P = 0.022 and 1.5, 95% CI 0.2 to 2.9, P = 0.030, respectively). There was also a significant difference of 13% in number of patients reporting global perceived effect at end of treatment (P = 0.016). None of the other secondary outcomes showed statistically significant differences. Conclusion. In patients with low back pain for more than 6 weeks presenting with centralization or peripheralization of symptoms, we found the McKenzie method to be slightly more effective than manipulation when used adjunctive to information and advice.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Rheumatology

Evaluating the Construct of Damage in Systemic Lupus Erythematosus

Sindhu R. Johnson, Dafna D. Gladman, Hermine Brunner, David Isenberg, Ann E. Clarke, Megan R. W. Barber, Laurent Arnaud, Paul R. Fortin, Marta Mosca, Alexandre E. Voskuyl, Susan Manzi, Cynthia Aranow, Anca Askanase, Graciela S. Alarcon, Sang-Cheol Bae, Nathalie Costedoat-Chalumeau, Jessica A. English, Guillermo J. Pons-Estel, Bernardo A. Pons-Estel, Rebecca Gilman, Ellen M. Ginzler, John G. Hanly, Soren Jacobsen, Kenneth Kalunian, Diane L. Kamen, Chynace Lambalgen, Alexandra Legge, S. Sam Lim, Anselm Mak, Eric F. Morand, Christine A. Peschken, Michelle Petri, Anisur Rahman, Rosalind Ramsey-Goldman, John A. Reynolds, Juanita Romero-Diaz, Guillermo Ruiz-Irastorza, Jorge Sanchez-Guerrero, Elisabet Svenungsson, Zahi Touma, Murray Urowitz, Evelyne Vinet, Ronald F. van Vollenhoven, Heather Waldhauser, Daniel J. Wallace, Asad Zoma, Ian N. Bruce

Summary: The SLICC, ACR, and Lupus Foundation of America are developing a revised SLE damage index (SDI) due to shifts in the concept of damage in SLE. A qualitative study was conducted to evaluate contemporary constructs in SLE damage and develop a conceptual framework for the revised SDI.

ARTHRITIS CARE & RESEARCH (2023)

Article Rheumatology

Longitudinal analysis of ANA in the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort

May Yee Choi, Ann Elaine Clarke, Murray Urowitz, John Hanly, Yvan St-Pierre, Caroline Gordon, Sang-Cheol Bae, Juanita Romero-Diaz, Jorge Sanchez-Guerrero, Sasha Bernatsky, Daniel J. Wallace, David Isenberg, Anisur Rahman, Joan T. Merrill, Paul R. Fortin, Dafna D. Gladman, Ian N. Bruce, Michelle Petri, Ellen M. Ginzler, Mary Anne Dooley, Rosalind Ramsey-Goldman, Susan Manzi, Andreas Jonsen, Graciela S. Alarcon, Ronald F. van Vollenhoven, Cynthia Aranow, Meggan Mackay, Guillermo Ruiz-Irastorza, Sam Lim, Murat Inanc, Ken Kalunian, Soren Jacobsen, Christine Peschken, Diane L. Kamen, Anca Askanase, Jill P. Buyon, Karen H. Costenbader, Marvin J. Fritzler

Summary: In a longitudinal analysis of a large international incident SLE cohort, three ANA assays demonstrated high positivity rates and commutability. However, over a 5-year follow-up, there was a modest variation in ANA assay performance.

ANNALS OF THE RHEUMATIC DISEASES (2022)

Article Rheumatology

Multiomics analysis of rheumatoid arthritis yields sequence variants that have large effects on risk of the seropositive subset

Saedis Saevarsdottir, Lilja Stefansdottir, Patrick Sulem, Gudmar Thorleifsson, Egil Ferkingstad, Gudrun Rutsdottir, Bente Glintborg, Helga Westerlind, Gerdur Grondal, Isabella C. Loft, Signe Bek Sorensen, Benedicte A. Lie, Mikael Brink, Lisbeth Arlestig, Asgeir Orn Arnthorsson, Eva Baecklund, Karina Banasik, Steffen Bank, Lena Bjorkman, Torkell Ellingsen, Christian Erikstrup, Oleksandr Frei, Inger Gjertsson, Daniel F. Gudbjartsson, Sigurjon A. Gudjonsson, Gisli H. Halldorsson, Oliver Hendricks, Jan Hillert, Estrid Hogdall, Soren Jacobsen, Dorte Vendelbo Jensen, Helgi Jonsson, Alf Kastbom, Ingrid Kockum, Salome Kristensen, Helga Kristjansdottir, Margit H. Larsen, Asta Linauskas, Ellen-Margrethe Hauge, Anne G. Loft, Bjorn R. Ludviksson, Sigrun H. Lund, Thorsteinn Markusson, Gisli Masson, Pall Melsted, Kristjan H. S. Moore, Heidi Munk, Kaspar R. Nielsen, Gudmundur L. Norddahl, Asmundur Oddsson, Thorunn A. Olafsdottir, Pall Olason, Tomas Olsson, Sisse Rye Ostrowski, Kim Horslev-Petersen, Solvi Rognvaldsson, Helga Sanner, Gilad N. Silberberg, Hreinn Stefansson, Erik Sorensen, Inge J. Sorensen, Carl Turesson, Thomas Bergman, Lars Alfredsson, Tore K. Kvien, Soren Brunak, Kristjan Steinsson, Vibeke Andersen, Ole A. Andreassen, Solbritt Rantapaa-Dahlqvist, Merete Lund Hetland, Lars Klareskog, Johan Askling, Leonid Padyukov, Ole Bv Pedersen, Unnur Thorsteinsdottir, Ingileif Jonsdottir, Kari Stefansson

Summary: This study identified causal genes for rheumatoid arthritis (RA) and its subsets through a genome-wide association study. Most of these genes encode proteins related to interferon and IL-12/23 signaling, particularly in the JAK/STAT pathway. Variants in some of these genes were found to increase or decrease the risk of seropositive RA.

ANNALS OF THE RHEUMATIC DISEASES (2022)

Review Medicine, Research & Experimental

Comparison of immune checkpoint inhibitor-induced arthritis and reactive arthritis to inform therapeutic strategy

Anders Kirkegaard Jensen, Katerina Chatzidionysiou, Christopher Kirkegaard Torp, Anne Sofie Sorensen, Helene Broch Tenstad, Valentin S. Schafer, Marie Kostine, Soren Jacobsen, Jan Leipe, Tue Wenzel Kragstrup

Summary: This literature review compares the pharmacological management of immune checkpoint inhibitor-induced inflammatory arthritis (ICI-IA) and reactive arthritis (ReA). The studies suggest that non-steroidal anti-inflammatory drugs (NSAIDs), glucocorticoids (GC), methotrexate (MTX), sulfasalazine (SSZ), and tumor necrosis factor alpha inhibition (TNFi) have shown effectiveness in both diseases.

BIOMEDICINE & PHARMACOTHERAPY (2022)

Article Rheumatology

Assessing the Costs of Neuropsychiatric Disease in the Systemic Lupus International Collaborating Clinics Cohort Using Multistate Modeling

Ann E. Clarke, John G. Hanly, Murray B. Urowitz, Yvan St. Pierre, Caroline Gordon, Sang-Cheol Bae, Juanita Romero-Diaz, Jorge Sanchez-Guerrero, Sasha Bernatsky, Daniel J. Wallace, David A. Isenberg, Anisur Rahman, Joan T. Merrill, Paul R. Fortin, Dafna D. Gladman, Ian N. Bruce, Michelle Petri, Ellen M. Ginzler, Mary Anne Dooley, Rosalind Ramsey-Goldman, Susan Manzi, Andreas Jonsen, Graciela S. Alarcon, Ronald F. Van Vollenhoven, Cynthia Aranow, Meggan Mackay, Guillermo Ruiz-Irastorza, S. Sam Lim, Murat Inanc, Kenneth C. Kalunian, Soren Jacobsen, Christine A. Peschken, Diane L. Kamen, Anca Askanase, Vernon Farewell

Summary: The objective of this study was to estimate the costs associated with neuropsychiatric events in SLE. The study found that new/ongoing SLE or non-SLE NP events incurred higher direct and indirect costs. Indirect costs exceeded direct costs by 3.0 to 5.2 fold.

ARTHRITIS CARE & RESEARCH (2023)

Article Rheumatology

Risk of End-Stage Renal Disease in Patients With Systemic Lupus Erythematosus and Diabetes Mellitus: A Danish Nationwide Cohort Study

Renata Baronaite Hansen, Titilola Falasinnu, Mikkel Faurschou, Soren Jacobsen, Julia F. Simard

Summary: This study aimed to determine whether diabetes mellitus (DM) increases the risk of end-stage renal disease (ESRD) in patients with systemic lupus erythematosus (SLE). The findings show that SLE patients with DM have a 3 times higher risk of developing ESRD compared to SLE patients without DM.

ARTHRITIS CARE & RESEARCH (2023)

Article Rheumatology

Machine learning identifies clusters of longitudinal autoantibody profiles predictive of systemic lupus erythematosus disease outcomes

May Yee Choi, Irene Chen, Ann Elaine Clarke, Marvin J. Fritzler, Katherine A. Buhler, Murray Urowitz, John Hanly, Yvan St-Pierre, Caroline Gordon, Sang-Cheol Bae, Juanita Romero-Diaz, Jorge Sanchez-Guerrero, Sasha Bernatsky, Daniel J. Wallace, David Alan Isenberg, Anisur Rahman, Joan T. Merrill, Paul R. Fortin, Dafna D. Gladman, Ian N. Bruce, Michelle Petri, Ellen M. Ginzler, Mary Anne Dooley, Rosalind Ramsey-Goldman, Susan Manzi, Andreas Jonsen, Graciela S. Alarcon, Ronald F. van Vollenhoven, Cynthia Aranow, Meggan Mackay, Guillermo Ruiz-Irastorza, Sam Lim, Murat Inanc, Kenneth Kalunian, Soren Jacobsen, Christine Peschken, Diane L. Kamen, Anca Askanase, Jill P. Buyon, David Sontag, Karen H. Costenbader

Summary: A novel longitudinal clustering technique was used to analyze comprehensive autoantibody data from a large, well-characterised, multinational inception SLE cohort, in order to determine predictive profiles of clinical outcomes.

ANNALS OF THE RHEUMATIC DISEASES (2023)

Article Clinical Neurology

Myositis-related autoantibody profile and clinical characteristics stratified by anti-cytosolic 5' -nucleotidase 1A status in connective tissue diseases

Louise Pyndt Diederichsen, Line Vinderslev Iversen, Christoffer Tandrup Nielsen, Soren Jacobsen, Marie-Louise Hermansen, Nanna Witting, Rikke Cortes, Sine Sondergaard Korsholm, Markus Engebaek Krogager, Tina Friis

Summary: This study aimed to determine the prevalence and clinical associations of cN-1A autoantibodies in patients with connective tissue diseases. The results showed that cN-1A autoantibodies were predominantly found in patients with idiopathic inflammatory myopathies (IIM) and were associated with dysphagia in sporadic inclusion body myositis (sIBM) patients. Additionally, cN-1A positive non-IBM IIM patients had a milder disease course.

MUSCLE & NERVE (2023)

Article Virology

Elevated Antibody Titers to Epstein-Barr Virus and Cytomegalovirus in Patients with Drug-Induced Lupus

Julie Knudsen, Nicole Hartwig Trier, Anette Holck Draborg, Christoffer Tandrup Nielsen, Soren Jacobsen, Peter Hojrup, Gunnar Houen

Summary: SLE and DIL are autoimmune diseases associated with EBV and CMV infections, but they differ in onset and clinical symptoms. This study found significantly elevated IgG titers to EBV and CMV antigens in serum samples from SLE and DIL patients, as well as reduced total IgG titers, which may be related to lymphocytopenia commonly seen in SLE.

VIRUSES-BASEL (2023)

Article Microbiology

Neoehrlichia mikurensis in Danish immunocompromised patients: a retrospective cohort study

Rosa Maja Mohring Gynthersen, Mette Frimodt Hansen, Lukas Frans Ocias, Andreas Kjaer, Randi Fons Petersen, Sisse Rye Ostrowski, Lene Harritshoj, Soren Jacobsen, Ulrik Overgaard, Karen Angeliki Krogfelt, Anne-Mette Lebech, Helene Mens

Summary: The presence of N. mikurensis DNA was detected in immunocompromised patients in Denmark, highlighting the potential underdiagnosis of this bacterium in Danish patients.

ANNALS OF CLINICAL MICROBIOLOGY AND ANTIMICROBIALS (2023)

Article Medicine, General & Internal

Effect of a 12-week high-intensity exercise intervention: a comparison of cardiac exercise adaptations during biological disease-modifying antirheumatic drug treatment (TNF inhibitors vs IL-6 signalling inhibitors) in patients with rheumatoid arthritis - study protocol for a randomised controlled trial

Simon Jonck, Malte Lund Adamsen, Pil Hojgaard, Iben Elmerdahl Rasmussen, Helga Ellingsgaard, Morten Asp Vonsild Lund, Peter Godsk Jorgensen, Soren Jacobsen, Lars Kober, Niels Vejlstrup, Lene Dreyer, Bente Klarlund Pedersen, Ronan M. G. Berg, Regitse Hojgaard Christensen

Summary: The chronic inflammatory state in rheumatoid arthritis (RA) increases the risk of cardiovascular disease (CVD), with pro-inflammatory cytokines tumor necrosis factor (TNF) and interleukin 6 (IL-6) playing a vital role. Biological disease-modifying antirheumatic drugs (bDMARDs) may attenuate that risk. IL-6 is also a myokine, secreted from exercising skeletal muscles, where it exhibits anti-inflammatory effects that may mitigate the risk of CVD. We hypothesize that inhibiting IL-6 signaling will impair the cardiac and metabolic adaptations to exercise training compared to TNF inhibition in RA patients.

BMJ OPEN (2023)

Article Rheumatology

Association Between Severe Nonadherence to Hydroxychloroquine and Systemic Lupus Erythematosus Flares, Damage, and Mortality in 660 Patients From the SLICC Inception Cohort

Yann Nguyen, Benoit Blanchet, Murray B. Urowitz, John G. Hanly, Caroline Gordon, Sang-Cheol Bae, Juanita Romero-Diaz, Jorge Sanchez-Guerrero, Ann E. Clarke, Sasha Bernatsky, Daniel J. Wallace, David A. Isenberg, Anisur Rahman, Joan T. Merrill, Paul R. Fortin, Dafna D. Gladman, Ian N. Bruce, Michelle Petri, Ellen M. Ginzler, Mary Anne Dooley, Rosalind Ramsey-Goldman, Susan Manzi, Andreas Joensen, Graciela S. Alarcon, Ronald F. Van Vollenhoven, Cynthia Aranow, Veronique Le Guern, Meggan Mackay, Guillermo Ruiz-Irastorza, S. Sam Lim, Murat Inanc, Kenneth C. Kalunian, Soren Jacobsen, Christine A. Peschken, Diane L. Kamen, Anca Askanase, Jill Buyon, Nathalie Costedoat-Chalumeau

Summary: The study aimed to assess the association between severe nonadherence to hydroxychloroquine (HCQ), analyzed by HCQ serum levels, and risks of systemic lupus erythematosus (SLE) flares, damage, and mortality rates. Severe nonadherence was found to be independently associated with increased risk of SLE flares, early damage, and five-year mortality.

ARTHRITIS & RHEUMATOLOGY (2023)

Article Rheumatology

ERN ReCONNET points to consider for treating patients living with autoimmune rheumatic diseases with antiviral therapies and anti-SARS-CoV-2 antibody products

R. Talarico, G. A. Ramirez, S. C. Barreira, C. Cardamone, P. Triggianese, S. Aguilera, J. Andersen, T. Avcin, K. Benistan, G. Bertsias, A. Bortoluzzi, C. Bouillot, I. Bulina, G. R. Burmester, S. Callens, P. E. Carreira, R. Cervera, M. Cutolo, L. Damian, E. Della Torre, R. Faria, J. E. Fonseca, I. Galetti, E. Hachulla, L. Iaccarino, S. Jacobsen, N. Khmelinskii, M. Limper, D. Marinello, A. Meyer, G. Moroncini, G. Nagy, M. Olesinska, C. Pamfil, M. Pileckyte, M. Pistello, S. Rednic, C. Richez, V. C. Romao, M. Schneider, S. Sciascia, C. A. Scire, G. Simonini, V. Smith, A. Sulli, C. Tani, S. W. Tas, A. Tincani, M. C. Vonk, M. Tektonidou, M. Mosca

Summary: Recent studies have shown that immunocompromised individuals may inadvertently contribute to the mutations of the virus that lead to new variants. This aspect should be carefully considered as immunocompromised individuals remain at risk of COVID-19 despite vaccination, experience more severe disease, and can be contagious for longer. The European Reference Network on Rare and Complex Connective Tissue and Musculoskeletal Diseases (ReCONNET) addressed this issue by forming a multidisciplinary Task Force to develop guidelines for treating immunocompromised patients with COVID-19. The final principles and points-to-consider were agreed upon by the Task Force.

CLINICAL AND EXPERIMENTAL RHEUMATOLOGY (2023)

Article Cardiac & Cardiovascular Systems

Myocardial fibrosis associates with lupus anticoagulant in patients with systemic lupus erythematosus

Katrine A. Myhr, Amanda H. Zinglersen, Redi Pecini, Soren Jacobsen

Summary: This study aimed to investigate the prevalence and degree of myocardial fibrosis in SLE patients. The results showed that SLE patients displayed signs of myocardial fibrosis on CMR, which were associated with the presence of lupus anticoagulant (LAC).

INTERNATIONAL JOURNAL OF CARDIOVASCULAR IMAGING (2023)

No Data Available